EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks

Diana A Gorog iD, Jurrien M Ten Berg, Gianluca Campo, Tobias Geisler, Bruna Gigante iD, Erik L Grove, Sigrun Halvorsen, Kurt Huber iD, Young-Hoon Jeong iD, Gregory Y H Lip, Eliano P Navarese, Andrea Rubboli iD und 7 weitere

European Heart Journal: Acute Cardiovascular Care · 28.04.2026 · 15 (4) · 337-363

DOI: 10.1093/ehjacc/zuag021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, online erschienen am 31.03.2026. Verfasst von Diana A Gorog und 18 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, United Kingdom. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Fibrinolytic Agents, Secondary Prevention. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 133 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual antiplatelet therapy (DAPT) is required to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). The default DAPT strategy, namely a potent P2Y12 inhibitor combined with aspirin for 12 months, exposes many patients to excess bleeding risk. Over the past years, alternative antithrombotic regimens have been proposed to reduce bleeding (DAPT abbreviation or de-escalation) or ischaemic (prolonged dual antithrombotic therapy) events. Abbreviation or de-escalation of DAPT is supported by (i) multiple trials showing these strategies to significantly reduce bleeding, particularly for the 20–40% of patients classified as high bleeding risk (HBR); (ii) low prevalence of stent thrombosis and recurrent myocardial infarction beyond 1–3 months post-ACS with the latest generation of drug-eluting stents, and (iii) the recognition that HBR is far more prevalent than high ischaemic risk. Amongst patients at HBR, standard DAPT, in comparison to abbreviated or de-escalated DAPT, increases the net risk of major adverse events, even in the presence of high ischaemic risk. Conversely, amongst patients at high ischaemic risk, without HBR, prolonged dual antithrombotic therapy reduces longer-term thrombotic risk. Recognizing risk factors and assessing the magnitude of bleeding and ischaemic risks are essential. Since there are no ideal scoring systems to balance ischaemic and bleeding risks, and many overlap, focus should be on managing the risk most amenable to modification, namely bleeding, which should dominate the decision-making over ischaemic risk when choosing a DAPT regimen. This document provides practical advice regarding best practice for personalizing DAPT in patients with ACS undergoing PCI, with evidence-based clinical consensus statements on selecting the most appropriate antiplatelet strategy to optimize clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionFibrinolytic AgentsSecondary PreventionHemorrhageHumansPlatelet Aggregation InhibitorsDual Anti-Platelet TherapyPrecision MedicineRisk Factors

Substanzen

Fibrinolytic AgentsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine, National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, United Kingdom.
  • Centre for Health Services Research, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire AL10 9AB, United Kingdom.
  • St Antonius Hospital, St Antonius Hospital, Nieuwegein, The Netherlands.
  • Cardiology Department, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Cardiology Division, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy.
  • Department of Cardiology and Angiology, University Hospital, Tübingen, Germany.

ORCID-Profile: Diana A Gorog, Bruna Gigante, Kurt Huber, Young-Hoon Jeong, Andrea Rubboli, Robert F Storey, Christophe Vandenbriele, Gemma Vilahur, Jose Luis Ferreiro

Zitieren

APA

Gorog, D. A., Ten Berg, J. M., Campo, G., Geisler, T., Gigante, B., Grove, E. L., Halvorsen, S., Huber, K., Jeong, Y. H., Lip, G. Y. H., Navarese, E. P., Rubboli, A., Siller Matula, J. M., Storey, R. F., Valgimigli, M., Vandenbriele, C., Vilahur, G., Ahrens, I., & Ferreiro, J. L. (2026). Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. European Heart Journal: Acute Cardiovascular Care, 15(4), 337-363. https://doi.org/10.1093/ehjacc/zuag021

Vancouver

Gorog DA, Ten Berg JM, Campo G, Geisler T, Gigante B, Grove EL, et al. Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. European Heart Journal: Acute Cardiovascular Care. 2026;15(4):337-363. doi:10.1093/ehjacc/zuag021

BibTeX
@article{Gorog2026,
  author = {Gorog, Diana A and Ten Berg, Jurrien M and Campo, Gianluca and Geisler, Tobias and Gigante, Bruna and Grove, Erik L and Halvorsen, Sigrun and Huber, Kurt and Jeong, Young-Hoon and Lip, Gregory Y H and Navarese, Eliano P and Rubboli, Andrea and Siller Matula, Jolanta M and Storey, Robert F and Valgimigli, Marco and Vandenbriele, Christophe and Vilahur, Gemma and Ahrens, Ingo and Ferreiro, Jose Luis},
  title = {Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {337--363},
  doi = {10.1093/ehjacc/zuag021}
}
Kostenlos starten →